October 2006 Edit List

Article

October 2006 Edit List

Features

REFRACTIVE

Phakic IOLs: the right fit?
David R. Hardten, MD

Phakic IOLs: when things go wrong
Michael C. Knorz, MD

The battle of the giants: Tecnis versus ReSTOR
Beatrice Cochener, MD

Exchanging lenses for clear vision
Magda Rau, MD

Hyperopic presbyopia: a new term for an old problem and its modern solution
Zissis Bisogiannis, MD

RETINA

Avastin: all it's cracked up to be?
Fedra Pavlou

Vitrectomy for ocular diabetic complications: a terminal event?
Paul Tesha & Somnath Banerjee

PAEDIATRIC

Silicone hydrogel contact lenses: a viable option for children?
Jolanta Bendoriene, MD

GLAUCOMA

One site or two? The big question for combined cataract and glaucoma surgeries
Z. Mandic, J. Korcic, K. Novak-Laus, M. Zoric-Geber, G. Bencic

ECP: consider it earlier!
Phillip Bloom, MD

Phaco therapy for glaucoma patients?
M.M. Pravosudova & L.I. Balashevich

Regulars

In Focus

Eye on Industry

Society Spotlight

Product Watch

Letters

Events Calendar

*Subject to the Editor's discretion

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Related Content
An image of the planet Earth encircled by a DNA strand. Concept image for global inherited retinal disease research collaboration, Opus Genetics and RDH12 alliance. Image credit: ©JohanSwanepoel – stock.adobe.com

Opus Genetics, Global RDH12 Alliance announce new collaboration

Kassi Filkins
August 5th 2025
Article

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

August 5th 2025
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach

Joong Hun Kim, MD
August 5th 2025
Article

In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

August 5th 2025
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Two people sit at a table. Their hands are visible, as are computers, pencils, notebooks, clipboards and documents. Concept image for business merger, licensing partnership, work collaboration, commercialisation throughout Europe, Re-Vana Therapeutics and Boehringer Ingelheim ocular eye drug therapy. Image credit: ©NAMPIX – stock.adobe.com

Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership

Lynda Charters
August 5th 2025
Article

The companies will focus their joint effort on extended-release therapies for ocular disease

The retina undergoing fundus imaging. Concept image for retinal imgaging, OCT, CA, cardiac angiography, optical coherence tomography and biomarkers. Image credit: ©Panama – stock.adobe.com

Biomarkers of microvascular retinal perfusion indicating coronary heart disease

Lynda Charters
August 5th 2025
Article

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

© 2025 MJH Life Sciences

All rights reserved.